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Abstract
The E3 ubiquitin ligase RING finger protein 115 (RNF115), also known as breast cancer–associated gene 2 (BCA2),
has previously been reported to be overexpressed in estrogen receptor α (ERα)–positive breast tumors and to pro-
mote breast cell proliferation; however, its mechanism is unknown. In this study, we demonstrated that silencing of
BCA2 by small interfering RNAs (siRNAs) in two ERα-positive breast cancer cell lines, MCF-7 and T47D, decreases cell
proliferation and increases the protein levels of the cyclin-dependent kinase inhibitor p21Waf/Cip1. The protein stability
of p21 was negatively regulated by BCA2. BCA2 directly interacts with p21 and promotes p21 ubiquitination and
proteasomal degradation. Knockdown of p21 partially rescues the cell growth arrest induced by the BCA2 siRNA.
These results suggest that BCA2 promotes ERα-positive breast cancer cell proliferation at least partially through
downregulating the expression of p21.
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Introduction
Protein ubiquitination is one of the crucial posttranslational modifica-
tions regulating the cell cycle progression. An ubiquitin E3 ligase,
such as SCFSKP2, SCFFBW7, and APC/C, is responsible for conjugating
ubiquitins to several specific proteins and usually targets them for
proteasomal degradation. Among over 600 E3 ligases, a couple of
them function as either oncoproteins or tumor suppressors. For exam-
ple, the SKP2 oncoprotein promotes cell cycle progression by targeting
the cyclin-dependent kinase (CDK) inhibitors p27Kip1 and p21Waf/Cip1
(below as p21) for ubiquitin-mediated degradation [1,2]. In contrast,
the FBW7 tumor suppressor inhibits cell cycle progression through pro-
moting the degradation of cyclin E [3,4], Myc [5,6], and Krüppel-like
factor 5 (KLF5) [7]. Identification of the cancer-related E3 ligases and
their substrates may provide more therapeutic targets for cancer treatment.
Previous studies showed that a novel characterized E3 ubiquitin
ligase, RING finger protein 115 (RNF115), also namely breast
cancer–associated gene 2 (BCA2), is overexpressed in breast cancer
and its expression is significantly correlated with positive estrogen re-
ceptor α (ERα) status [8]. A recent study discovered that BCA2 is an
ERα direct downstream target gene [9]. BCA2 has been demonstrated
to increase proliferation of the T47D human breast cancer cell line
[8]. Although several BCA2 interacting proteins, such as Rab7, tetherin,
ubiquitin, UBC9, hHR23a, and 14-3-3σ, have been identified by yeast
two-hybrid screening [10–12], the mechanisms by which BCA2 pro-
motes breast cancer cell proliferation are still unclear.
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The CDK inhibitor p21 controls the cell cycle progression through
inhibiting the activity of several cyclin-CDK complexes [13]. Its
transcription is tightly regulated by multiple transcription factors,
including p53, Myc, Smad, and KLF4 [14,15]. Previous studies
demonstrated that the p21 protein level is also tightly controlled by
multiple E3 ligases, including SCFSkp2 [2], CRL4Cdt2 [16], APC/
CCdc20 [17], MKRN1 [18], and RNF126 [19].
Since RNF126 and BCA2 have a high-sequence identity [20],
we hypothesize that BCA2 promotes ERα-positive breast cancer
cell proliferation through targeting p21 for ubiquitin-mediated
degradation. In this study, we demonstrated that depletion of
BCA2 significantly increased the p21 protein levels and decreased
DNA synthesis in two ERα-positive breast cancer cell lines, BCA2
promotes p21 ubiquitination and degradation in an E3 ligase
activity–dependent manner, and depletion of p21 partially rescued
the BCA2 small interfering RNA (siRNA)–induced growth arrest.
These findings suggest that BCA2 promotes ERα-positive breast
cancer cell proliferation partially through targeting p21 for ubiquitin-
mediated degradation.
Materials and Methods
Cell Lines and Cell Culture
MCF-7 and T47D cells were purchased from American Type
Culture Collection (Manassas, VA) and cultured according to
American Type Culture Collection recommended condition.
Human embryonic kidney HEK293FT cells (R700-07; Invitrogen,
Carlsbad, CA) were maintained in Dulbecco’s modified Eagle’s
medium (Hyclone), supplemented with 10% FBS, 1% penicillin,
and 1% streptomycin.
Plasmids, siRNAs, and Transfection
The Flag-tagged wild-type (WT) and RING domain mutant (C228
and C231 residues were mutated into A) constructs of BCA2 have
been described in our previous study [10]. The mammalian HA-p21–
expressing plasmid was kindly provided by Dr Tiebang Kang [21].
For constructing glutathione S -transferase (GST)–BCA2–expressing
plasmids, the full-length and truncated sequences of BCA2 were in-
serted into the pEBG vector through BamHI/NotI sites. The siRNAs
targeting the BCA2 gene were synthesized by Ambion (Austin, TX),
and the targeting sequences were AGACAAUACCACAACAACAtt
(siBCA2-A#, S26038) and GAAUAUAUAUGUCCCAGAUtt
(siBCA2-B#, S26036), respectively. The siRNA targeting the firefly
luciferase gene (siLuc) was used as the negative control. Lipofectamine
2000 (Invitrogen) was used to transfect plasmids and siRNAs according
to the manufacturer’s instructions.
Semiquantitative Reverse Transcription–Polymerase
Chain Reaction
The mRNA levels of BCA2, p21, p53, and p27 were examined by
semiquantitative reverse transcription–polymerase chain reaction (RT-
PCR) in MCF-7 and T47D. After transfected by siLuc and siBCA2,
total RNAs were prepared from cultured cells using TRIzol reagents
(15596-026; Invitrogen). RT of 1 μg of total RNA was performed
using the iScript cDNA Synthesis Kit (170-8891; Bio-Rad, Hercules,
CA). The primers for RT-PCR were given as follows: primers for BCA2,
forward—5′-TGTCCCAGATGTGAATCAGG-3′ and reverse—
5′-TGGAGATCTGTCAGGACGAG-3′; primers for p21, forward—
5′-GCGATGGAACTTCGACTTTGT-3′ and reverse—5′-GGGCT-
TCCTCTTGGAGAAGAT-3′ ; primers for p27, forward—
5′-AGACGGGGTTAGCGGAGCAA-3′ and reverse—5′-TCTT-
GGGCGTCTGCTCCACA-3′; primers for p53, forward—
5′-CTGGCCCCTGTCATCTTCTG-3′ and reverse—5′-CGGC-
TCATAGGGCACCAC-3′; primers for glyceraldehyde-3-phosphate
dehydrogenase (GAPDH), as a loading control, forward—5′-GGTGA-
AGGTCGGAGTCAACG-3′ and reverse—5′-TGGGTGGAATCA-
TATTGGAACA-3′. PCR on cDNA products was performed using
the following parameters: predenaturation at 94°C for 2 minutes,
94°C for 30 seconds, annealing at 55°C for 30 seconds, elongation
at 72°C for 40 seconds, running 25 cycles, and final elongation at
72°C for 7 minutes. The PCR products were run on 2% agarose
gels and examined with an ImageQuant LAS4000 (GE Healthcare,
Piscataway, NJ).
Western Blot Analysis
Cells were washed once with pre-cold phosphate-buffered saline
(PBS) solution and lysed in cell lysis buffer [50 mM Tris-HCl
(pH 7.4), 150 mM NaCl, 1% Triton X-100, 1 mM EDTA, sup-
plemented with 1× protease inhibitor cocktail] on ice for 30 minutes.
The total protein concentration was analyzed with Bio-Rad DC Pro-
tein Assay Kit (500-0116), and equal amounts of proteins were run
on sodium dodecyl sulfate (SDS)–polyacrylamide gel electrophoresis
gels. After transferring to polyvinylidene difluoride (PVDF) mem-
branes and blocking with 5% nonfat milk, the targeted proteins were
immunoblotted with specific primary antibodies against BCA2 [8],
p53 (554169; BD Biosciences, San Jose, CA), p27 (610241; BD Bio-
sciences), p21 (2947; Cell Signaling Technology, Danvers, MA), ERα
(sc-7207; Santa Cruz Biotechnology, Dallas, TX), Flag tag (F3165;
Sigma, St Louis, MO), HA tag (sc-805; Santa Cruz Biotechnology),
GST (G7781; Sigma), andGAPDH(25778; SantaCruzBiotechnology),
respectively. To probe different target proteins in the same membrane,
the Restore Western Blot Stripping Buffer (21059; Pierce, Rockford,
IL) was used to strip the primary and secondary antibodies.
Flow Cytometry
T47D cells were digested by trypsin-EDTA solution, collected by
centrifugation at 500g for 5 minutes, and washed once with PBS. The
cells were treated with BD Cytofix/Cytoperm buffer (51-2090KZ; BD
Pharmingen) for 20 minutes at 4°C. The cells were washed twice with
PBS and then incubated with PBS solution containing 0.1 mg/ml
propidium iodide (PI) and 2 mg/ml RNase A for 30 minutes at 37°C.
The cells were analyzed for DNA contents by flow cytometry using
an Accuri C6 Flow Cytometer (BD Biosciences), and the data were
analyzed using FlowJo software.
Immunoprecipitation and GST Pull-Down
For exogenous interaction between p21 and Flag-BCA2, cell lysates
were directly incubated with anti-Flag M2 affinity gel (A2220; Sigma)
overnight at 4°C. For endogenous protein interaction, cell lysates were
first incubated with anti-p21 antibody or rabbit IgG (sc-2028; Santa
Cruz Biotechnology) and then incubated with Protein A/G plus-
agarose beads (sc-2003; Santa Cruz Biotechnology). For GST pull-
down assay, cell lysates were directly incubated with Glutathione
Sepharose 4B (52-2303-00; GE Healthcare) overnight at 4°C. The
precipitates were washed four times with 1 ml of lysis buffer, boiled
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for 10 minutes with 1× SDS sample buffer, and subjected to Western
blot (WB) analysis.
In Vivo Ubiquitination Assays
The in vivo ubiquitination assay was performed as a previous pro-
tocol [22]. Briefly, after transfecting with WT or mutant Flag-BCA2,
HA-p21, and 6× His-Myc-Ub expression plasmids (a gift from
Prof Raymond J. Deshaies of Caltech, Pasadena, CA) and treating
with 10 μM MG132 to inhibit the p21 degradation, 293FT cells
were lysed in warm SDS lysis buffer [50 mM Tris-HCl (pH 7.5),
1% SDS, 1 mM EDTA]. The lysates were boiled for 10 minutes
and were diluted 10-fold with dilution buffer [50 mM Tris-HCl
(pH 7.5), 1% SDS, 1 mM EDTA, 1 mM DTT, 0.5% NP-40, sup-
plemented with 1× protease inhibitor cocktail]. The protein lysates
were mixed with Ni-nitrilotriacetic acid (NTA) agarose (30210;
Qiagen, Germantown, MD) for 2 hours in a shaker at 4°C. The
precipitates were washed five times with washing buffer [50 mM
Tris-HCl (pH 7.4), 1% SDS, 1 mM EDTA, 1 mM DTT, 0.5%
NP-40] and were boiled for 10 minutes with 1× SDS sample buffer.
The protein samples were subjected to WB analysis.
Cell Proliferation and Cell Viability Assays
Cell proliferation of MCF-7 and T47D cells were performed with
the EdU incorporation assay using Click-iT EdU Alexa Fluor 647
Imaging Kit (10340; Invitrogen) according to the manufacturer’s guide-
lines. The cell viability was performed with the Sulforhodamine B
(SRB) assay.
Cycloheximide Chase Assays
To determine the half-life of p21 protein, cycloheximide (CHX)
chase assays were performed following previous protocols [19].
After transfection for 48 hours, cells were treated for 0, 15, 35,
and 60 minutes with 50 μg/ml CHX and collected for WB analysis.
Statistical Analysis
All experiments were performed at least three times, and data were
performed as the means ± SD. The differences between any two
groups were analyzed by t test. The P values of less than .05 were
considered statistically significant.
Results
BCA2 Promotes Cell Proliferation in the MCF-7 and
T47D Breast Cancer Cell Lines
Previous studies showed that the BCA2 protein is highly expressed
in ERα-positive breast cancer cell lines and tumors [8]. We first exam-
ined the BCA2 protein levels in two immortalized breast epithelial
cell lines, three ERα-negative cancer cell lines, and four ERα-positive
cancer cell lines by WB analysis. Consistent with a previous report
[19], the BCA2 protein was highly expressed in two ERα-positive
breast cancer cell lines MCF-7 and T47D (Figure 1A). Following
this, we knocked down BCA2 in MCF-7 and T47D by two different
siRNAs, siBCA2-A# and siBCA2-B# (Figure 1B), and measured cell
growth by the SRB assay. Comparing to the mock and siLuc control,
Figure 1. Knockdown of BCA2 inhibits breast cancer cell proliferation, DNA synthesis, and cell cycle. (A) WB analysis of BCA2 protein levels
in a panel of immortalized breast epithelial cell lines and ERα-negative and ERα-positive breast cancer cell lines. GAPDH was used as
a loading control. (B) MCF-7 and T47D cells were transfected for 72 hours with either Lipofectamine 2000 reagent as mock, control siLuc
RNA, siBCA2-A#, or siBCA2-B#. The knockdown effect was assessed byWB analysis, and cell viability was examined using the SRB assay
(**P < .01 compared to siLuc). (C) After silencing of BCA2 by siBCA2-A#, MCF-7 and T47D cells were pulse labeled with EdU Alexa Fluor
647 for 4 hours and were stained the nuclei with 10 μg/ml PI. The percentage of positive cells incorporated with EdU were shown in the
histograms (right side, **P< .01). All quantitative values were from triplicate experiments. (D) After silencing of BCA2 by siBCA2-A#, MCF-7
and T47D cells were harvested, fixed, stained with PI solution, and analyzed by flow cytometry. The percentage of arrest G1 phase cells
was shown in the histograms (*P < .05 and **P < .01).
Figure 2. BCA2 depletion upregulates the p21 expression at the protein level but not the mRNA level. (A) MCF-7 and T47D cells were
transfected with either siLuc or siBCA2 for 72 hours. Protein levels of BCA2, p21, p27, and p53 were analyzed by WB analysis. (B) The
mRNA levels of BCA2, p21, p27, and p53 were analyzed using semiquantitative RT-PCR. GAPDH was used as a loading control.
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BCA2 siRNAs significantly decreased the cell growth in both cell lines
(Figure 1B). Because BCA2 knockdown did not induce cell death in
these cells (data not shown), we examined the DNA synthesis by the
EdU incorporation experiments. As expected, the DNA synthesis of
both cell lines was dramatically inhibited by BCA2 siRNAs compared
to siLuc (Figure 1C ). Cell cycle analysis indicated that MCF-7 and
T47D cells were mainly arrested in the G1 phase (Figure 1D). These
results indicate that endogenous BCA2 promotes cell proliferation in
ERα-positive breast cancer cells.
BCA2 Suppresses the p21 Expression at the Protein Level
but Not the mRNA Level
To study the mechanism by which BCA2 promotes breast cancer
cell proliferation, we first investigated the protein levels of cell cycle–
regulatory proteins p21 and p27, because of the homology of BCA2
and RNF126, which has recently been shown by us to target p21 for
degradation [19]. Indeed, silencing of BCA2 in MCF-7 and T47D
specifically increased the p21 protein levels but not the p27 and
p53 protein levels (Figure 2A). To determine whether BCA2 regu-
lates p21 at the mRNA level, we first evaluated the mRNA levels of
p21 by using semiquantitative RT-PCR and found that there were
no significant changes for p21 after BCA2 was knocked down in
both MCF-7 and T47D (Figure 2B). The result was further con-
firmed by real-time PCR (Figure W1). Thus, BCA2 is likely to
regulate the p21 expression at the protein posttranslational level.
BCA2 Promotes p21 Protein Degradation through Proteasome
As an E3 ligase, BCA2 may promote the proteolysis of p21. To
test this, we cotransfected BCA2 and p21 into HEK293FT cells and
found that the p21 protein levels were dramatically downregulated by
BCA2 (Figure 3A). The BCA2-mediated p21 degradation was largely
blocked by the proteasome inhibitor MG132 (Figure 3A). We further
measured the protein half-lives of p21 by performing the CHX chase
assay. In MCF-7 cells, when BCA2 was knocked down by siRNA for
48 hours, the half-life of p21 protein was extended from 35.5 to
67.8 minutes (Figure 3B). In addition, we ectopically overexpressed
Flag-BCA2 and its RING finger mutant, Flag-BCA2-RINGm [10],
which does not have the E3 ubiquitin ligase activity, in HEK293FT
cells. As shown in Figure 3C , WT BCA2 shortened the half-life of
p21 protein from 65.5 to 47 minutes, while the RINGm BCA2 did
not significantly change the half-life of p21 protein. Thus, BCA2
promotes p21 protein degradation in an E3 ubiquitin ligase activity–
dependent manner.
BCA2 Interacts with p21 and Promotes Its Ubiquitination
To test whether BCA2 interacts with p21, we cotransfected Flag-
BCA2 and HA-p21 constructs into HEK293FT cells treated with
10 μM MG132 for 4 hours to prevent p21 degradation. When
Flag-BCA2 was immunoprecipitated by the anti-Flag M2 affinity
gel, HA-p21 was detected in the complex (Figure 4A). Without
Flag-BCA2, the HA-p21 protein could not be immunoprecipitated
Figure 3. (A) BCA2 promotes p21 protein degradation through proteasome. Flag-BCA2 and HA-p21 were cotransfected into HEK293FT
cells as indicated. The proteasome inhibitor MG132 (10 μM) was added to treat the cells for 8 hours if necessary. (B) After depletion of
BCA2 by siBCA2-A# in MCF-7 cells, the cells were exposed to CHX for a time as indicated, and WB analysis was performed. The quantita-
tive half-lives of p21 protein from two independent experiments are shown on the right side. (C) HEK293FT cells were cotransfected with
HA-p21 and WT BCA2 or RING finger mutant BCA2 expression plasmids. The BCA2-RINGm protein migrates much slower than WT BCA2
possibly because of the protein structure difference under the electrophoresis condition. The cells were exposed to CHX for a time
as indicated. The level of p21 protein was detected by WB analysis. The quantitative data from two independent experiments are shown
on the right side.
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(Figure 4A), indicating the specificity of interaction. To further test if
endogenous proteins also interact with each other, the endogenous p21
protein was immunoprecipitated by the anti-p21 antibody in MCF-7
cells, and the endogenous BCA2 was specifically co-immunoprecipitated
(Figure 4B). To investigate the detailed interaction, we constructed
GST-fused WT and four truncated BCA2 expression plasmids and
performed the GST pull-down assays. WT BCA2, BCA2 (1-225),
and BCA2 (1-46) pulled down p21 (Figure 4C). Consistently, BCA2
Figure 4. BCA2 interacts with p21 and promotes its ubiquitination. (A) The HA-p21 expression construct was transiently cotransfected
with an empty control or Flag-BCA2 expression plasmid into HEK293FT cells, respectively. After culturing for 48 hours, the cells were
exposed to 10 μM MG132 for 4 hours and collected for immunoprecipitation experiments using anti-Flag M2 affinity gel. The samples
were subjected to WB analysis using anti-Flag and anti-HA antibodies. Total cell lysates were used as the input control. (B) Cell lysates
from exponentially growing MCF-7 cells were immunoprecipitated with the anti-p21 antibody or the rabbit IgG control. Precipitates were
subjected to WB analysis with anti-p21 and anti-BCA2 antibodies. (C) The HA-p21 expression construct was transiently cotransfected
with a pEBG vector as a control, PEBG-BCA2 as a positive control, or truncated GST-BCA2 expression plasmids in HEK293FT cells,
respectively. Total cell lysates were collected 48 hours later and precipitated with Glutathione Sepharose 4B. The precipitated proteins
were subjected to WB analysis using anti-HA and anti-GST antibodies. Total cell lysates were used as the input control. (D) HEK293FT
cells were transiently cotransfected with a panel of expression plasmids as indicated. Forty-eight hours later, the cells were treated for
4 hours with 10 μM MG132 and lysed. The samples were precipitated with Ni-NTA agarose beads under a denaturing condition. The
proteins were subjected to WB analysis with anti-HA and anti-Flag antibodies.
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(47-225) failed to interact with p21. These results suggest that BCA2
interacts with p21 through the first 46 amino acid residues (Figure 4C).
To determine whether BCA2 promotes the p21 protein degrada-
tion through ubiquitination, we cotransfected a panel of expression
plasmids, including Flag-BCA2/Flag-BCA2 RINGm, HA-p21, and
6× His-Myc-Ub, into HEK293FT cells and examined the p21
ubiquitination. WT BCA2 obviously increased the ubiquitination
level of p21 protein compared to the empty vector control and BCA2
RINGm (Figure 4D).
BCA2 Promotes Breast Cancer Cell Proliferation Partially
through Downregulating the Expression of p21
BCA2 may ubiquitinate multiple substrates. We sought to deter-
mine whether BCA2 functions through p21. Rescue experiments
were performed in MCF-7 and T47D cells. Since BCA2 knockdown
increased the p21 protein levels in both cell lines, we silenced the
expression of both p21 and BCA2 and found that p21 knockdown
partially but significantly restored the BCA2 siRNA–induced growth
arrest in both cell lines (Figure 5).
Because BCA2 has been reported to be a direct target gene of ER
[9], we further tested whether BCA2-mediated p21 degradation
is regulated by estrogen. As shown in Figure W2, estrogen treat-
ment for 24 hours induced degradation of ERα but only slightly
increased the BCA2 and p21 protein levels in MCF-7. Knockdown
of BCA2 dramatically increased the p21 protein levels independent
of estrogen treatment.
Discussion
In eukaryotic cells, activities of each member of the CDK family are
specifically controlled by the availability of its cyclin partners and the
CDK inhibitors, such as p21, p27, and p57 [23]. Deregulation of
cyclins or CDK inhibitors results in aberrant cell cycle progression
and cell proliferation, eventually causing cancer initiation and pro-
gression. Ubiquitin-mediated proteasomal degradation plays crucial
roles on controlling the abundance of these cell cycle regulators [24].
In this study, we demonstrated that BCA2 is a novel E3 ubiquitin
ligase for p21 because BCA2 interacts with p21 and increased the
Figure 5. BCA2 promotes breast cancer cell proliferation partially through downregulating the expression of p21. MCF-7 and T47D cells
were transiently transfected with siLuc, sip21, and siBCA2 siRNA, as indicated. Cell lysates were collected 72 hours later and subjected
to WB analysis. Protein levels of p21 and BCA2 in MCF-7 (A) or T47D (B) were shown. The cell viability was measured by the SRB assay
and shown in the graphs, respectively, (A) MCF-7 or (B) T47D (**P < .01).
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p21 protein ubiquitination and degradation in an E3 ligase activity–
dependent manner. Consistently, depletion of BCA2 promotes breast
cancer cell proliferation.
A recent study showed that the transcription of BCA2 was induced
by estrogen through ERα binding to the estrogen-responsive elements
at the BCA2 gene promoter in MCF-7 cells [9]. This is consistent
with our previous study in which the protein expression of BCA2
was correlated with positive ERα status. We verified that BCA2 was
highly expressed in two ERα-positive breast cancer cell lines MCF-7
and T47D and further demonstrated that BCA2 promoted cell pro-
liferation in these cells. However, we also found that the induction
of BCA2 by estrogen in MCF-7 is modest (Figure W2) and deple-
tion of BCA2 also decreased cell viability in the ERα-negative MDA-
MB-231 breast cancer cell line and PC-3 prostate cancer cell line in
an E3 ligase siRNA screening [19]. Thus, BCA2 may promote cell
proliferation regardless of the ERα status.
The BCA2 protein shares 46% sequence homology with RNF126,
a newly characterized E3 ligase targeting p21 [19]. Both BCA2 and
RNF126 share a similar protein structure based on sequence iden-
tity [20]. Both proteins interact with p21 through their N-terminal
fragments and promote p21 protein ubiquitination and degradation
through their RING finger domains. However, RNF126 is highly
expressed in ERα-negative breast cancer cell lines but lowly expressed
in ERα-positive breast cancer cell lines including MCF-7 and T47D
[19]. In contrast, BCA2 is predominately expressed in ERα-positive
breast cancer cell lines and tumors. Thus, they seem to play a simi-
lar role in different types of breast cancers. How BCA2, RNF126,
and other E3 ligases coordinately regulate the protein level of p21 in
cell type–, cell cycle–, and other context-dependent manners needs
further investigation.
Besides p21, several other BCA2 interacting proteins, including
Rab7, tetherin, ubiquitin, UBC9, hHR23a, and 14-3-3σ have been
identified [20]. However, BCA2 appears not to target these proteins
for ubiquitin-mediated degradation. It is significant to identify the
physiological substrates for BCA2 to fully elucidate the function and
mechanism of BCA2 in breast cancer and other diseases.
In conclusion, we demonstrated that BCA2, a potential oncogenic
E3 ubiquitin ligase, promotes breast cancer cell proliferation partially
through targeting p21 for ubiquitination and proteasomal degradation.
These findings provide a mechanistic insight for BCA2 function in
breast cancer.
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